#ESMO26 Dr. Byoung Cho @cbcbc1971 shows simplified dermatologic prophylaxis in COCOON with 1L SC amivantamab + lazertinib for EGFR+ NSCLC had reduction in dermatologic AEs similar to full regimen - this can reduce treatment burden. Lazertinib lead-in for 1 cycle even better.
85 views · 2 likes · 2 reposts · 0 replies
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.orgSource: Stephen V Liu, MD · x.com